Julie Brown - Smith Nephew CFO, Director and Member of Disclosures Committee

SNN Stock  USD 25.52  0.82  3.11%   

Director

Ms. Julie Brown is no longer Chief Financial Officer Executive Director of Smith Nephew PLC. effective January 31 2017. She is a graduate Chartered Accountant and Fellow of the Institute of Taxation. She trained with KPMG before working at AstraZeneca PLC where she served as Vice President Group Finance and ultimately as Interim Chief Financial Officer. Prior to that she was Regional Vice President Latin America Marketing Company President AstraZeneca Portugal and Vice President Corporationrationrate Strategy and RD Chief Financial Officer. In both Julies country and regional roles trading margins increased significantly improving the efficiency and profitability of the business. Her experience encompasses many areas of the healthcare value chain including Commercial Operations RD and Business Development. She has led multibillion dollar cost saving and restructuring programmes in Operations RD and the Commercial organisations and led major refinancing programmes including the issuance of 2 billion US bonds. Julie has so far in her career fulfilled two Nonexecutive Directorships with the NHS in the UK and the Board of the British Embassy. since 2013.
Age 52
Tenure 11 years
Professional MarksMBA
Address Building 5, Watford, United Kingdom, WD18 8YE
Phone44 1923 477 100
Webhttps://www.smith-nephew.com

Smith Nephew Management Efficiency

The company has Return on Asset of 0.0427 % which means that on every $100 spent on assets, it made $0.0427 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.0502 %, implying that it generated $0.0502 on every 100 dollars invested. Smith Nephew's management efficiency ratios could be used to measure how well Smith Nephew manages its routine affairs as well as how well it operates its assets and liabilities. As of the 28th of March 2024, Return On Capital Employed is likely to drop to 0.12. In addition to that, Return On Assets is likely to drop to 0.03. At this time, Smith Nephew's Total Assets are very stable compared to the past year. As of the 28th of March 2024, Non Current Assets Total is likely to grow to about 6.3 B, while Other Current Assets are likely to drop about 87.4 M.
The company has 3.08 B in debt with debt to equity (D/E) ratio of 0.54, which is OK given its current industry classification. Smith Nephew SNATS has a current ratio of 1.74, which is typical for the industry and considered as normal. Debt can assist Smith Nephew until it has trouble settling it off, either with new capital or with free cash flow. So, Smith Nephew's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Smith Nephew SNATS sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Smith to invest in growth at high rates of return. When we think about Smith Nephew's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

DIRECTOR Age

Samir KaulGuardant Health
44
Donna ZarconeCigna Corp
63
Sanders WilliamsLaboratory
69
Jane HenneyCigna Corp
69
JeanLuc BelingardLaboratory
72
Gary GillilandLaboratory
63
Pascal GoldschmidtMednax Inc
65
John PartridgeCigna Corp
71
Waldemar CarloMednax Inc
67
Stanley MeresmanGuardant Health
71
Eric FossCigna Corp
62
Eric WisemanCigna Corp
65
Roman MartinezCigna Corp
71
Robert WilliamsLaboratory
72
Aaref HilalyGuardant Health
46
Mark McClellanCigna Corp
57
James RogersCigna Corp
69
Karey BarkerMednax Inc
52
Mary HoeltzelCigna Corp
N/A
Jeffrey DavisLaboratory
57
Michelle GassCigna Corp
47
Smith Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices worldwide. Smith Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom. Smith Nephew operates under Medical Devices classification in the United States and is traded on New York Stock Exchange. It employs 18000 people. Smith Nephew SNATS (SNN) is traded on New York Stock Exchange in USA. It is located in Building 5, Watford, United Kingdom, WD18 8YE and employs 18,452 people. Smith Nephew is listed under Health Care Equipment & Supplies category by Fama And French industry classification.

Management Performance

Smith Nephew SNATS Leadership Team

Elected by the shareholders, the Smith Nephew's board of directors comprises two types of representatives: Smith Nephew inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Smith. The board's role is to monitor Smith Nephew's management team and ensure that shareholders' interests are well served. Smith Nephew's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Smith Nephew's outside directors are responsible for providing unbiased perspectives on the board's policies.
Michael Friedman, Non-Executive Independent Director
Helen Barraclough, Company Counsel
Gunthorp Oie, IR Contact Officer
Roland Diggelmann, Chief Executive Officer, Executive Director
Helen Maye, Chief Human Resources Officer
Vinita Bali, Non-Executive Independent Director
Simon Fraser, President - Advanced Wound Management and Global Commercial Operations
Massimiliano Colella, President Europe - Middle East and Africa
Olivier Bohuon, CEO, Director, Chairman of Disclosures Committee, Chairman of Executive Risk Committee and Member of Nomination and Governance Committee
Graham Baker, Chief Financial Officer, Executive Director
Cathy ORourke, Chief Legal and Compliance Officer
Ian Melling, Interim Chief Financial Officer
Roberto Quarta, Non-Executive Independent Chairman of the Board
Joe Metzger, Senior Communications
Rick Medlock, Non-Executive Independent Director
Glenn Warner, President - Advanced Wound Management
Paul Connolly, President Operations
Phil Cowdy, Executive Vice President of Business Development & Corporate Affairs
Angie Risley, Non-Executive Independent Director
Mark Gladwell, President - Global Operations and Global Business Services
John Ma, Non-Executive Independent Director
Vasant Padmanabhan, President - Research & Development
Joseph Papa, Non-Executive Independent Director
Susan Swabey, Company Secretary
Melissa Guerdan, Chief Quality and Regulatory Affairs Officer
Philip Cowdy, Chief Officer
Ian Barlow, Non-Executive Independent Director
Namal Nawana, Chief Executive Officer, Executive Director
Bob White, Non-Executive Independent Director
Diogo MoreiraRato, President - Europe and Canada
Alison Parkes, Chief Officer
Skip Kiil, President - Orthopedics
Erik Engstrom, Non-Executive Independent Director
Deepak Nath, Chief Executive Officer
Matthew Stober, President - Global Operations
Marc Owen, Non-Executive Independent Director
AnneFrancoise Nesmes, Chief Financial Officer, Executive Director
Rodrigo Bianchi, Interim President - Asia Pacific
Brian Larcombe, Senior Independent Non-Executive Director
Elga Lohler, Chief Human Resource Officer
Bradley Cannon, President Orthopaedics
Katarzyna MazurHofsaess, Non-Executive Independent Director
Cyrille Petit, Chief Corporate Development Officer
Julie Brown, CFO, Director and Member of Disclosures Committee
Peter Coenen, President - EMEA Region
Robin Freestone, Senior Non-Executive Independent Director
Virginia Bottomley, Non-Executive Independent Director
Myra Eskes, President - Asia Pacific
Andrew Swift, Vice Relations
Michael Frazzette, President - Advanced Surgical Devices
Ingeborg Oie, VP, Investor Relations
Gordon Howe, President of Global Operations
John Campo, Chief Legal Officer
Brad Cannon, President - Sports Medicine & ENT
Jo Hallas, Non-Executive Director
Catheryn ORourke, Chief Legal and Compliance Officer

Smith Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Smith Nephew a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Smith Nephew in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Smith Nephew's short interest history, or implied volatility extrapolated from Smith Nephew options trading.

Currently Active Assets on Macroaxis

When determining whether Smith Nephew SNATS offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Smith Nephew's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Smith Nephew Snats Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Smith Nephew Snats Stock:
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Smith Nephew SNATS. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors.
You can also try the Latest Portfolios module to quick portfolio dashboard that showcases your latest portfolios.

Complementary Tools for Smith Stock analysis

When running Smith Nephew's price analysis, check to measure Smith Nephew's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Smith Nephew is operating at the current time. Most of Smith Nephew's value examination focuses on studying past and present price action to predict the probability of Smith Nephew's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Smith Nephew's price. Additionally, you may evaluate how the addition of Smith Nephew to your portfolios can decrease your overall portfolio volatility.
Bonds Directory
Find actively traded corporate debentures issued by US companies
Fundamental Analysis
View fundamental data based on most recent published financial statements
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Top Crypto Exchanges
Search and analyze digital assets across top global cryptocurrency exchanges
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Commodity Directory
Find actively traded commodities issued by global exchanges
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Is Smith Nephew's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Smith Nephew. If investors know Smith will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Smith Nephew listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
0.983
Dividend Share
0.375
Earnings Share
0.6
Revenue Per Share
2.5484
Quarterly Revenue Growth
0.076
The market value of Smith Nephew SNATS is measured differently than its book value, which is the value of Smith that is recorded on the company's balance sheet. Investors also form their own opinion of Smith Nephew's value that differs from its market value or its book value, called intrinsic value, which is Smith Nephew's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Smith Nephew's market value can be influenced by many factors that don't directly affect Smith Nephew's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Smith Nephew's value and its price as these two are different measures arrived at by different means. Investors typically determine if Smith Nephew is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Smith Nephew's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.